Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis - Cleavage of leukocyte C5A receptor

被引:0
|
作者
Jagels, MA
Ember, JA
Travis, J
Potempa, J
Pike, R
Hugli, TE
机构
[1] UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602
[2] JAGIELLONIAN UNIV,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,KRAKOW,POLAND
来源
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The anaerobic bacteria P. gingivalis has been implicated as a primary causative agent in adult periodontitis. Several proteinases are produced by this bacteria and it is suggested that they contribute to virulence and to local tissue injury resulting from infection by P. gingivalis, Collagenases and cysteine proteinases (i.e., the gingipains)* have been characterized as the predominant vesicular enzymes produced by this bacterium. It has been shown that an arginine-specific cysteine proteinase from P. gingivalis, called gingipain-1 or Arg-gingipain, can selectively cleave complement components C3 and C5. In the case of C5, cleavage by Arg-gingipain results in the generation of C5a, a potent chemotactic factor for PMNs. Since these bacterial proteinases are capable of generating pro-inflammatory factors at sites of infection, we examined the possibility that gingipains or other proteinases from this bacterium might attack or destroy cell surface proteins, such as receptor molecules. Using an affinity-purified rabbit antibody raised against residues 9-29 of the C5a receptor (i.e., C5aR; CD88), the signal transmitting element for the pro-inflammatory mediator C5a, we demonstrated that the mixture of proteinases in P. gingivalis vesicles cleaves the C5a receptor on human neutrophils. This vesicular proteinase activity did not require cysteine activation which indicates that proteinases other than the gingipains may be responsible for cleavage of the C5aR molecule. In addition, the purified Lys-gingipain, but not Arg-gingipain, also cleaved C5aR on the human neutrophils. The N-terminal region of C5aR (residues 9-29, PDYGHYDDKDTLDLNTPVDKT) was readily cleaved by chymotrypsin, but not by trypsin, despite the presence of potential trypsin (i.e., lysyl-X) cleavage sites. The specific sites of C5aR 9-29 peptide cleavage were determined by mass spectroscopy for both chymotrypsin and Lys-gingipain. These studies suggest that the proteolytic activity in the bacterial vesicles that is responsible for cleaving C5aR is primarily a non-tryptic proteinase, distinct from either Arg- or Lys-gingipain. Consequently, there appear to be additional proteinase(s) in the vesicles that attacks the cell surface molecule C5aR which are not the same (i.e., Arg- and Lys-gingipain) as were shown to generate pro-inflammatory activity from complement components C3 and C5. Evidence that the proteinases which attack the inflammatory precursor molecules (i.e., C3 and C5) exhibit different specificities than those that attack receptors to these bioactive complement products makes a particularly interesting story of how this bacteria avoids major host defense mechanisms. It is well known that generation of pro-inflammatory factors such as C3a and C5a at extra-vascular sites can promote edema, leukocyte recruitment and cellular activation responses that could lead to the release of toxic oxygen products and to phagocytosis of the bacteria. Destruction of receptors to these cellular activating factors generated by bacterial proteinases may eliminate the ability of these (i.e., complement-derived) and other mediators to carry out their anti-bacterial actions and thereby limit the host's defense mechanisms in responses to the infecting bacteria. The concept of anti-bacterial responses (i.e., oxygen radical generation and phagocytosis) being effectively eliminated at the injury site, by bacterial proteinases acting at the cellular receptor level, has not been studied in detail. In this case, the situation is particularly unusual because, once the bacterial gingipains generate potent plasma-derived inflammatory factors that can enhance edema and deliver essential nutrients to the bacteria, other bacterial proteinases may destroy their cellular receptors. These receptors transmit the signal activation mechanisms in the infiltrating cells that elicit bacterial killing. It is this series of events which might explain the ability of these anaerobes to persist and flourish in gingival tissue.
引用
收藏
页码:155 / 164
页数:10
相关论文
共 50 条
  • [1] Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis
    Jagels, MA
    Travis, J
    Potempa, J
    Pike, R
    Hugli, TE
    INFECTION AND IMMUNITY, 1996, 64 (06) : 1984 - 1991
  • [2] HUMAN C5A AND C5A ANALOGS AS PROBES OF THE NEUTROPHIL C5A RECEPTOR
    CHENOWETH, DE
    HUGLI, TE
    MOLECULAR IMMUNOLOGY, 1980, 17 (02) : 151 - 161
  • [3] IDENTIFICATION OF THE POLYMORPHONUCLEAR LEUKOCYTE C5A RECEPTOR
    ROLLINS, TE
    SPRINGER, MS
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1985, 260 (12) : 7157 - 7160
  • [4] THE AMINO-TERMINUS OF THE HUMAN C5A RECEPTOR IS REQUIRED FOR HIGH-AFFINITY C5A BINDING AND FOR RECEPTOR ACTIVATION BY C5A BUT NOT C5A ANALOGS
    DEMARTINO, JA
    VANRIPER, G
    SICILIANO, SJ
    MOLINEAUX, CJ
    KONTEATIS, ZD
    ROSEN, H
    SPRINGER, MS
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (20) : 14446 - 14450
  • [5] C5A RECEPTOR
    HUEY, R
    HUGLI, TE
    METHODS IN ENZYMOLOGY, 1987, 150 : 615 - 627
  • [6] ANALYSIS OF THE HUMAN-LEUKOCYTE C5A RECEPTOR USING FLUORESCENT C5A AND FLOW-CYTOMETRY
    VANEPPS, DE
    CHENOWETH, DE
    LEWIS, SL
    FEDERATION PROCEEDINGS, 1983, 42 (03) : 424 - 424
  • [7] Human T cells express the C5a receptor and are chemoattracted to C5a
    Nataf, S
    Davoust, N
    Ames, RS
    Barnum, SR
    JOURNAL OF IMMUNOLOGY, 1999, 162 (07): : 4018 - 4023
  • [8] LEUKOCYTE C5A RECEPTOR MODULATION DURING HEMODIALYSIS
    LEWIS, SL
    VANEPPS, DE
    CHENOWETH, DE
    KIDNEY INTERNATIONAL, 1987, 31 (01) : 112 - 120
  • [9] INITIAL CHARACTERIZATION OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE (PMN) C5A RECEPTOR
    CHENOWETH, DE
    HUGLI, TE
    JOURNAL OF IMMUNOLOGY, 1978, 120 (05): : 1768 - 1768
  • [10] C5a receptor antagonists
    Pellas, TC
    Wennogle, LP
    CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (10) : 737 - 755